RESUMO
Aim: Ketamine is an anesthetic agent that at lower doses can be a potent analgesic. There has been an interest in the use of low dose ketamine in treatment of chronic pain syndromes. Patients & methods: We report the results of a retrospective observational study for patients diagnosed with a chronic noncancer pain syndrome receiving a 2-week continuous subanesthetic IV ketamine infusion. Results & conclusion: We conclude that a 10-14 days of subanesthetic ketamine infusion in chronic patients results in clinically significant lowering of patients' numerical pain score. Further studies looking at subanesthetic ketamine infusion in a prospective trial of multi-day IV ketamine infusion in chronic refractory chronic neuropathic pain are needed to further assess the efficacy of ketamine.
Ketamine is a pharmacological agent that was developed in the 1960s. There has been an increase in interest in the use of ketamine at low doses in the treatment of chronic pain syndromes. In this study, we report the results of a study that investigated patients diagnosed with a chronic noncancer pain syndrome that received a 2-week continuous ketamine infusion. We hypothesized that patients receiving IV ketamine infusion will experience acute and chronic lowering of pain intensity on the numerical rating pain level scale and reduce patient's opioid requirements. We concluded that a 1014 day of subanesthetic ketamine infusion in chronic patients results in clinically significant lowering of patients' numerical pain score during the ketamine infusion.
Assuntos
Dor Crônica , Ketamina , Analgésicos , Analgésicos Opioides/uso terapêutico , Dor Crônica/tratamento farmacológico , Humanos , Ketamina/uso terapêutico , Estudos ProspectivosRESUMO
PURPOSE OF REVIEW: To provide an overview of the current treatment strategies for common subtypes of post-stroke pain. RECENT FINDINGS: There is growing research interest in non-pharmacological treatment approaches for chronic pain, including neurostimulation as well as lifestyle and psychosocial interventions. Newer pharmacotherapy research includes cannabinoids and NMDA-receptor antagonists as well as bee venom. Persistent post-stroke headache is an increasingly appreciated entity, though the role of novel chronic migraine treatments for post-stroke headache is not known. Overall, most treatment approaches to post-stroke pain lack high-quality evidence. Stroke survivors are in need of effective treatments based on methodologically sound evidence. To address the interplay of clinical and psychosocial factors that contribute to post-stroke pain, it may be reasonable to adopt a multimodal treatment strategy incorporating both lifestyle interventions and conventional therapies.
Assuntos
Manejo da Dor/métodos , Dor/complicações , Dor/tratamento farmacológico , Acidente Vascular Cerebral/complicações , HumanosRESUMO
PURPOSE OF REVIEW: To provide an updated review on cold stimulus headache. RECENT FINDINGS: Age, type of stimulus, comorbidities, and study design but not necessarily gender appear to influence the reported prevalence of cold stimulus headache (CSH). Different cold stimuli appear to provoke different types of CSH. Ice water appears to provoke more frequent and higher pain intensity with a shorter latency compared to CSH provoked by ice cubes. Cold stimulus headache is very common unusual headache with limited literature. The severity, frequency, and latency appear to be influenced by the speed and size of the exposed area.